MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Alimentary Pharmacology and Therapeutics' source. Wed, 08 Feb 2012 14:03:58 +0100 http://www.medworm.com/index.php?rid=5667340&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.05001.x ConclusionsIndividuals with coeliac disease have lower BMI than the regional population at diagnosis. BMI increases on the GFD, especially in those that adhere closely to the GFD. On the GFD, 15.8% of patients move from a normal or low BMI class into an overweight BMI class, and 22% of patients overweight at diagnosis gain weight. These results indicate that weight maintenance counselling should be an integral part of coeliac dietary education. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5667340 Wed, 08 Feb 2012 18:13:33 +0100 5667340 http://www.medworm.com/index.php?rid=5667342&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.05000.x ConclusionsLarger randomised clinical studies with adequate statistical power are needed to confirm these potentially very important nonskeletal effects of vitamin D in patients with chronic hepatitis C. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5667342 Wed, 08 Feb 2012 05:00:00 +0100 5667342 http://www.medworm.com/index.php?rid=5667341&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.05007.x ConclusionsA major functional dysbiosis was observed in constipated‐irritable bowel syndrome gut microbiota, reflecting altered intestinal fermentation. Sulphate‐reducing population increased in the gut of C‐IBS and were accompanied by alterations in other microbial groups. This could be responsible for changes in the metabolic output and enhancement in toxic sulphide production which could in turn influence gut physiology and contribute to IBS pathogenesis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5667341 Wed, 08 Feb 2012 05:00:00 +0100 5667341 http://www.medworm.com/index.php?rid=5667344&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.05002.x ConclusionEndoscopic and clinical postoperative recurrence remains common in patients with Crohn's disease, and the identification of risk factors may allow targeted strategies to reduce this recurrence rate. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5667344 Tue, 07 Feb 2012 05:00:00 +0100 5667344 http://www.medworm.com/index.php?rid=5667343&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.05006.x ConclusionsDrugs with antihaemostatic action are re‐prescribed to a large extent after an episode of upper gastrointestinal bleeding, but usually covered by PPIs. This use of PPI is specific for users of drugs with antihaemostatic action. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5667343 Tue, 07 Feb 2012 05:00:00 +0100 5667343 http://www.medworm.com/index.php?rid=5659909&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04988.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5659909 Sun, 05 Feb 2012 18:00:10 +0100 5659909 http://www.medworm.com/index.php?rid=5659908&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04941.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5659908 Sun, 05 Feb 2012 18:00:08 +0100 5659908 http://www.medworm.com/index.php?rid=5659907&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04991.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5659907 Sun, 05 Feb 2012 18:00:06 +0100 5659907 http://www.medworm.com/index.php?rid=5648021&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04992.x ConclusionsThese UK Consensus guidelines indicate the current best practice for the use of boceprevir and telaprevir in the management of genotype 1 chronic HCV infection. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5648021 Wed, 01 Feb 2012 05:00:00 +0100 5648021 http://www.medworm.com/index.php?rid=5648023&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04997.x ConclusionsAntibodies to infliximab titres decline to undetectable levels within one year of cessation of infliximab in the majority of patients, whereas antibodies to adalimumab seem to persist longer after adalimumab discontinuation. Measuring antibodies to infliximab prior to infliximab re‐induction is probably of little clinical utility, especially if more than a 12‐month drug‐holiday has elapsed. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5648023 Mon, 30 Jan 2012 05:00:00 +0100 5648023 http://www.medworm.com/index.php?rid=5648022&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04998.x ConclusionsThe overall risk of malignancy in coeliac patients declines with time after diagnosis and is not significantly increased after 15 years. Most of the increased risk can be attributed to the development of haematological malignancies, despite their very low absolute rate of occurrence. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5648022 Mon, 30 Jan 2012 05:00:00 +0100 5648022 http://www.medworm.com/index.php?rid=5628762&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04993.x ConclusionsLong‐term suppression of HDV RNA by IFNa is not maintained despite an end of treatment response; adding lamivudine is not beneficial. PEG‐IFNa is superior to other medications with respect to EOT and EOFUP. New RCTs should test combinations of PEG‐IFNa and newest antivirals. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5628762 Thu, 26 Jan 2012 18:34:11 +0100 5628762 http://www.medworm.com/index.php?rid=5608999&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04996.x ConclusionsThe SOFA score is superior to MELD in predicting spontaneous survival following paracetamol‐induced acute liver injury. Modification of the MELD score to include serum sodium does not improve prognostic accuracy in this setting. SOFA may have potential as a quantitative triage marker following paracetamol overdose. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5608999 Fri, 20 Jan 2012 18:09:11 +0100 5608999 http://www.medworm.com/index.php?rid=5609000&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2012.04994.x ConclusionMolecular adsorbent recirculating system therapy delivered in an ‘out‐patient’ setting is safe and effective with a high degree of patient acceptability. Albumin dialysis can be considered a viable therapeutic option for patients with severe intractable pruritus, in whom, the only other effective treatment option is liver transplantation. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5609000 Fri, 20 Jan 2012 05:00:00 +0100 5609000 http://www.medworm.com/index.php?rid=5609002&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04989.x Conclusions(i) Funding sources and conflicts of interest are still reported variably in the GI literature. (ii) Editorials and review articles are influential, but have poor reporting of conflicts of interest. (iii) Editors of many journals still do not report their conflicts of interest. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5609002 Thu, 19 Jan 2012 05:00:00 +0100 5609002 http://www.medworm.com/index.php?rid=5609001&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04990.x ConclusionsAll the oral anti‐viral agents were associated with improved virological, biochemical and clinical parameters at 1‐year. However, the efficacy of lamivudine and telbivudine is limited by drug resistance, and adefovir is limited by its potency and slower onset of action. Additional studies of tenofovir and entecavir are needed to determine the optimal agent(s) for treatment naïve patients and in those with drug‐resistant decompensated HBV cirrhosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5609001 Thu, 19 Jan 2012 05:00:00 +0100 5609001 http://www.medworm.com/index.php?rid=5609004&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04987.x ConclusionsHigh baseline CRP levels increased the likelihood of maintained remission. Normalised CRP levels at week 14 increased the likelihood of maintained response or remission during 1 year of infliximab maintenance therapy (Clinical trial: NCT00207662). (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5609004 Wed, 18 Jan 2012 05:00:00 +0100 5609004 http://www.medworm.com/index.php?rid=5609003&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04983.x ConclusionIn patients with irritable bowel syndrome with constipation, lubiprostone 8 mcg twice daily was found to be safe and well tolerated over 9–13 months of treatment. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5609003 Wed, 18 Jan 2012 05:00:00 +0100 5609003 http://www.medworm.com/index.php?rid=5597916&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04974.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597916 Tue, 17 Jan 2012 18:43:37 +0100 5597916 http://www.medworm.com/index.php?rid=5597915&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04981.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597915 Tue, 17 Jan 2012 18:43:35 +0100 5597915 http://www.medworm.com/index.php?rid=5597914&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04963.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597914 Tue, 17 Jan 2012 18:43:33 +0100 5597914 http://www.medworm.com/index.php?rid=5597913&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04959.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597913 Tue, 17 Jan 2012 18:43:31 +0100 5597913 http://www.medworm.com/index.php?rid=5597912&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04964.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597912 Tue, 17 Jan 2012 18:43:29 +0100 5597912 http://www.medworm.com/index.php?rid=5597911&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04949.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597911 Tue, 17 Jan 2012 18:43:28 +0100 5597911 http://www.medworm.com/index.php?rid=5597909&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04982.x ConclusionThis proteomic analysis identified differentially expressed proteins that are components of pathways previously implicated in the pathogenesis of idiosyncratic drug‐induced liver injury. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597909 Tue, 17 Jan 2012 18:42:56 +0100 5597909 http://www.medworm.com/index.php?rid=5597910&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04979.x ConclusionsAcupuncture is effective in the treatment of functional dyspepsia, and is superior to non‐acupoint puncture. The benefit of acupuncture relies on acupoint specificity. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5597910 Mon, 16 Jan 2012 05:00:00 +0100 5597910 http://www.medworm.com/index.php?rid=5581976&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04986.x Conclusions:A significant proportion of ambulatory patients with UC treated with maintenance infliximab required therapy escalation over time. This was associated with lower remission, and higher colectomy, rates. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581976 Fri, 13 Jan 2012 23:00:09 +0100 5581976 http://www.medworm.com/index.php?rid=5581979&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04972.x ConclusionsPatients with coeliac disease are at an increased risk of mortality and non‐Hodgkin lymphoma, particularly T‐cell non‐Hodgkin lymphoma; they do not have an increased risk of any malignancy overall. Serologically defined patients with coeliac disease have an elevated risk of mortality and non‐Hodgkin lymphoma. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581979 Fri, 13 Jan 2012 05:00:00 +0100 5581979 http://www.medworm.com/index.php?rid=5581978&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04975.x ConclusionsAbout 1 in 10 patients may be exposed to potentially harmful levels of diagnostic medical radiation. Corticosteroid use and IBD related surgery increased this risk. Strategies to reduce radiation exposure while assessing disease activity need to be considered. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581978 Fri, 13 Jan 2012 05:00:00 +0100 5581978 http://www.medworm.com/index.php?rid=5581977&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04978.x ConclusionsThere is modest evidence for the benefit of antidepressants in reducing NCCP and improving patients’ general health. However, there is significant heterogeneity amongst the studies with several study limitations to warrant more rigorous trials and to assess the usefulness of low‐dose antidepressants in non‐GERD NCCP. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581977 Fri, 13 Jan 2012 05:00:00 +0100 5581977 http://www.medworm.com/index.php?rid=5581982&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04977.x ConclusionsRectal relaxation following dosing with sildenafil 50 mg increased the first desire to defecate threshold in IBS as a whole, but decreased pain only in the hypersensitive subset. Mixed‐IBS presented higher supraliminar pain and anxiety‐depression scores. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581982 Tue, 10 Jan 2012 05:00:00 +0100 5581982 http://www.medworm.com/index.php?rid=5581981&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04984.x ConclusionsCommunity‐acquired Clostridium difficile infection can be associated with complications and poor outcomes, including hospitalisation and severe Clostridium difficile infection. As the incidence of community‐acquired Clostridium difficile infection increases, clinicians should be aware of risk factors (increasing age, comorbid conditions and disease severity) that predict the need for hospitalisation and complications in patients with community‐acquired Clostridium difficile infection. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581981 Tue, 10 Jan 2012 05:00:00 +0100 5581981 http://www.medworm.com/index.php?rid=5581980&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04980.x ConclusionsLiterature on the pathophysiology of exercise‐induced GI‐symptoms is scarce. Increased sympathetic nervous system activity and decreased splanchnic blood flow during physical exercise seems to be the key factor in the pathogenesis of exercise‐induced GI‐symptoms, and this should be the target for symptom reduction. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581980 Tue, 10 Jan 2012 05:00:00 +0100 5581980 http://www.medworm.com/index.php?rid=5572256&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04971.x ConclusionsThe gastrointestinal renin‐angiotensin system appears to be intricately involved in a number of physiological processes, and provides a possible target for novel investigative and therapeutic approaches. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5572256 Sun, 08 Jan 2012 18:00:02 +0100 5572256 http://www.medworm.com/index.php?rid=5581984&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04970.x ConclusionThis trial shows a positive effect on symptoms in constipated patients after intake of probiotic‐enriched artichokes (clinical trial NCT01212146). (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581984 Fri, 06 Jan 2012 05:00:00 +0100 5581984 http://www.medworm.com/index.php?rid=5581983&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04973.x ConclusionsA quantitative serum HBsAg level at 12 weeks of therapy can be used for the early prediction of SR to peginterferon therapy in HBeAg‐negative CHB patients infected with genotype B or C. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581983 Fri, 06 Jan 2012 05:00:00 +0100 5581983 http://www.medworm.com/index.php?rid=5560292&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04957.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560292 Thu, 05 Jan 2012 14:02:50 +0100 5560292 http://www.medworm.com/index.php?rid=5560291&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04940.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560291 Thu, 05 Jan 2012 14:02:49 +0100 5560291 http://www.medworm.com/index.php?rid=5560290&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04947.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560290 Thu, 05 Jan 2012 14:02:47 +0100 5560290 http://www.medworm.com/index.php?rid=5560289&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04954.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560289 Thu, 05 Jan 2012 14:02:45 +0100 5560289 http://www.medworm.com/index.php?rid=5560288&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04942.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560288 Thu, 05 Jan 2012 14:02:44 +0100 5560288 http://www.medworm.com/index.php?rid=5560287&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04961.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560287 Thu, 05 Jan 2012 14:02:42 +0100 5560287 http://www.medworm.com/index.php?rid=5560286&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04943.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560286 Thu, 05 Jan 2012 14:02:40 +0100 5560286 http://www.medworm.com/index.php?rid=5560285&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04960.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560285 Thu, 05 Jan 2012 14:02:39 +0100 5560285 http://www.medworm.com/index.php?rid=5560284&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04921.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560284 Thu, 05 Jan 2012 14:02:37 +0100 5560284 http://www.medworm.com/index.php?rid=5560283&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04958.x Conclusions  Chronic treatment with AV608 in IBS is associated with improved mood and pain ratings and activity of emotional arousal related brain regions. This suggests that further exploration of NK1R antagonists is warranted in visceral pain disorders, particularly in patients with comorbid anxiety symptoms. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560283 Thu, 05 Jan 2012 14:02:32 +0100 5560283 http://www.medworm.com/index.php?rid=5560282&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04968.x ConclusionIn this study, coeliac disease was associated with a moderately increased risk of urinary stone disease both before and after coeliac disease diagnosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5560282 Thu, 05 Jan 2012 14:02:21 +0100 5560282 http://www.medworm.com/index.php?rid=5581985&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04965.x ConclusionsProgress in the field will require an improved understanding of how the microbiota impacts on health and disease, adequately powered long‐term multicentre trials and the embracing of bench to bedside approaches. Recent incremental advances suggest these areas are being addressed and that the future holds much promise for the use of lactic acid bacteria in the treatment of irritable bowel syndrome. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5581985 Thu, 05 Jan 2012 05:00:00 +0100 5581985 http://www.medworm.com/index.php?rid=5572259&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04969.x ConclusionsOur study confirms an inverse association between H. pylori and IBD and a positive association between the H. pylori – negative gastritis and IBD. These relationships may open new avenues to study the pathogenesis of IBD. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5572259 Thu, 05 Jan 2012 05:00:00 +0100 5572259 http://www.medworm.com/index.php?rid=5572258&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04966.x ConclusionsLong‐term high dose ursodeoxycholic acid does not prevent colorectal cancer or dysplasia in patients with primary sclerosing cholangitis‐associated inflammatory bowel disease. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5572258 Thu, 05 Jan 2012 05:00:00 +0100 5572258 http://www.medworm.com/index.php?rid=5572257&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04967.x ConclusionsThe four decision‐making nodes in the algorithm for the management of pregnancy in the IBD patient, and the key points for each one are as follows: (i) preconception counselling – pregnancy outcome is better if patients remain in remission during pregnancy, (ii) contemplating pregnancy or is already pregnant – drugs used to treat IBD appear to be safe during pregnancy, with the exception of methotrexate and thalidomide, (iii) delivery and (iv) breast feeding – drugs used to treat IBD appear to be safe during lactation, except for ciclosporin. Another key point is that biological agents may be continued up to 30 weeks gestation. The management of pregnancy in the IBD patient should be multi‐disciplinary involving the patient and her partner, the family physician, the g... Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5572257 Thu, 05 Jan 2012 05:00:00 +0100 5572257 http://www.medworm.com/index.php?rid=5552423&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04962.x Conclusion  The diagnostic accuracy of both tests individually reflects expected geno/phenotypes when the populations are well defined. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5552423 Sat, 31 Dec 2011 07:41:36 +0100 5552423 http://www.medworm.com/index.php?rid=5544668&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04955.x Conclusions  Pregabalin attenuates development of secondary hypersensitivity in the proximal oesophagus after distal oesophageal acidification; it may thus have a role in treatment of patients with proven oesophageal pain hypersensitivity. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5544668 Wed, 28 Dec 2011 09:45:15 +0100 5544668 http://www.medworm.com/index.php?rid=5538164&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04946.x Conclusions  Over one‐third adalimumab‐treated patients are dose escalated within a median of 5 months. Higher BMI and secondary non‐response to IFX treatment are predictive for a dose escalation during adalimumab treatment. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5538164 Sun, 25 Dec 2011 06:36:23 +0100 5538164 http://www.medworm.com/index.php?rid=5515572&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04956.x Conclusions  The use of complementary and alternative medicine is widely prevalent among IBD patients, and is more frequent among those who experience from adverse effects of conventional medications. From this cross‐sectional analysis, complementary and alternative medicine use does not appear to be associated with reduced overall adherence to medical therapy. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5515572 Mon, 19 Dec 2011 06:22:04 +0100 5515572 http://www.medworm.com/index.php?rid=5515574&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04948.x Conclusions  Most IBS patients change subtype over time. However, an underlying stool pattern stability was demonstrated in the majority of patients. To increase stability, we recommend 2‐week data for IBS subtyping. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5515574 Sun, 18 Dec 2011 05:00:00 +0100 5515574 http://www.medworm.com/index.php?rid=5515573&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04950.x Conclusions  Remission of erosive oesophagitis is maintained with omeprazole treatment for at least 21 months in most children aged 1–16 years, and the drug is well tolerated. To maintain remission, some 60% of patients require more than half the dose required for healing. In children with GERD‐predisposing conditions, GERD is often chronic and relapsing, and requires long‐term management. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5515573 Sun, 18 Dec 2011 05:00:00 +0100 5515573 http://www.medworm.com/index.php?rid=5505020&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04931.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505020 Fri, 16 Dec 2011 06:34:23 +0100 5505020 http://www.medworm.com/index.php?rid=5505019&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04930.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505019 Fri, 16 Dec 2011 06:34:21 +0100 5505019 http://www.medworm.com/index.php?rid=5505018&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04913.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505018 Fri, 16 Dec 2011 06:34:19 +0100 5505018 http://www.medworm.com/index.php?rid=5505017&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04935.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505017 Fri, 16 Dec 2011 06:34:18 +0100 5505017 http://www.medworm.com/index.php?rid=5505016&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04936.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505016 Fri, 16 Dec 2011 06:34:16 +0100 5505016 http://www.medworm.com/index.php?rid=5505015&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04933.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505015 Fri, 16 Dec 2011 06:34:14 +0100 5505015 http://www.medworm.com/index.php?rid=5505014&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04945.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505014 Fri, 16 Dec 2011 06:34:13 +0100 5505014 http://www.medworm.com/index.php?rid=5505013&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04928.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5505013 Fri, 16 Dec 2011 06:34:11 +0100 5505013 http://www.medworm.com/index.php?rid=5486983&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04879.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486983 Sat, 10 Dec 2011 06:46:29 +0100 5486983 http://www.medworm.com/index.php?rid=5486982&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04917.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486982 Sat, 10 Dec 2011 06:46:28 +0100 5486982 http://www.medworm.com/index.php?rid=5486981&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04909.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486981 Sat, 10 Dec 2011 06:46:26 +0100 5486981 http://www.medworm.com/index.php?rid=5486980&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04899.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486980 Sat, 10 Dec 2011 06:46:25 +0100 5486980 http://www.medworm.com/index.php?rid=5486979&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04895.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486979 Sat, 10 Dec 2011 06:46:23 +0100 5486979 http://www.medworm.com/index.php?rid=5486978&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04920.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486978 Sat, 10 Dec 2011 06:46:21 +0100 5486978 http://www.medworm.com/index.php?rid=5486977&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04893.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486977 Sat, 10 Dec 2011 06:46:20 +0100 5486977 http://www.medworm.com/index.php?rid=5486976&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04919.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486976 Sat, 10 Dec 2011 06:46:18 +0100 5486976 http://www.medworm.com/index.php?rid=5486975&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04884.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486975 Sat, 10 Dec 2011 06:46:17 +0100 5486975 http://www.medworm.com/index.php?rid=5486974&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04900.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486974 Sat, 10 Dec 2011 06:46:15 +0100 5486974 http://www.medworm.com/index.php?rid=5486973&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04894.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486973 Sat, 10 Dec 2011 06:46:14 +0100 5486973 http://www.medworm.com/index.php?rid=5486972&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04891.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486972 Sat, 10 Dec 2011 06:46:12 +0100 5486972 http://www.medworm.com/index.php?rid=5486971&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04896.x Conclusion  Larger controlled clinical trials are needed to demonstrate any potential beneficial effect of sorafenib on portal hypertension in patients with cirrhosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486971 Sat, 10 Dec 2011 06:45:55 +0100 5486971 http://www.medworm.com/index.php?rid=5486970&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04905.x Conclusions  Based on the literature data, we provide a therapeutic algorithm for thiopurines therapy with starting dose recommendations depending on TPMT status and thereafter dose adjustments according to five metabolite profiles identified with therapeutic drug monitoring (TDM). This algorithm allows a dosage individualisation to optimise the management of patients under thiopurine. Furthermore, identification of new pharmacogenetic biomarkers is promising for ensuring maximal therapeutic response to thiopurines with a minimisation of the risk for adverse events. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486970 Sat, 10 Dec 2011 06:45:44 +0100 5486970 http://www.medworm.com/index.php?rid=5486969&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04953.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486969 Sat, 10 Dec 2011 06:45:41 +0100 5486969 http://www.medworm.com/index.php?rid=5486968&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04952.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486968 Sat, 10 Dec 2011 06:45:39 +0100 5486968 http://www.medworm.com/index.php?rid=5486967&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04939.x Conclusions  In children with active distal ulcerative colitis, rectal infusion of L. reuteri is effective in improving mucosal inflammation and changing mucosal expression levels of some cytokines involved in the mechanisms of inflammatory bowel disease. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5486967 Sat, 10 Dec 2011 06:45:18 +0100 5486967 http://www.medworm.com/index.php?rid=5476695&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04932.x Conclusions  Serum ASCA levels remain stable after curative intestinal resection in CD. This indicates the persistence of both stimulus and immunological mechanism operative in the production of ASCA even after complete surgical resection of macroscopically inflamed intestinal tissue. After intestinal resection, neither ASCA positivity nor ASCA serum levels predict the risk of surgical recurrence during long‐term follow‐up (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5476695 Tue, 06 Dec 2011 05:00:00 +0100 5476695 http://www.medworm.com/index.php?rid=5476696&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04934.x Conclusions  Treatment with infliximab makes it possible to avoid colectomy in two‐thirds of corticosteroid‐refractory UC patients in whom ciclosporin fails. However, the rates of adverse events and mortality mean that the decision to administer sequential therapy (ciclosporin–infliximab) should be taken on an individual basis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5476696 Mon, 05 Dec 2011 05:00:00 +0100 5476696 http://www.medworm.com/index.php?rid=5476694&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04938.x Conclusions  Although coeliac disease is the most common cause of DVA, noncoeliac enteropathy is not rare and may easily be mistaken for coeliac disease. Noncoeliac enteropathy is suggested by a normal initial tTG (87%), lack of intraepithelial lymphocytosis on biopsy, and lack of histological response to a gluten free diet. Subjective response to gluten free diet has poor predictive value for coeliac disease. Noncoeliac enteropathy can often be confirmed by negative HLA‐DQ2/DQ8 testing and targeted investigations can ascertain a definitive aetiology in most cases. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5476694 Thu, 01 Dec 2011 05:00:00 +0100 5476694 http://www.medworm.com/index.php?rid=5457885&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04937.x Conclusion  Rifabutin‐containing rescue therapy constitutes an encouraging strategy after multiple (usually three) previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5457885 Thu, 01 Dec 2011 05:00:00 +0100 5457885 http://www.medworm.com/index.php?rid=5457886&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04926.x Conclusions  Oral DHA supplementation is associated with an increase in serum DHA levels and a significant decline in alkaline phosphatase levels in patients with PSC. These data support the need for a rigorous trial of DHA therapy in PSC. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5457886 Wed, 30 Nov 2011 05:00:00 +0100 5457886 http://www.medworm.com/index.php?rid=5441183&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04929.x Conclusions  In NAFLD patients, visceral adiposity index is an expression of both qualitative and quantitative adipose tissue dysfunction and, together with insulin resistance, is independently correlated with significant fibrosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441183 Fri, 25 Nov 2011 06:28:39 +0100 5441183 http://www.medworm.com/index.php?rid=5441188&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04924.x Conclusions  The NAFLD was associated with poor bone health in obese children. More severe disease was associated with lower bone mineralisation. Further studies are needed to evaluate the underlying mechanisms and consequences of poor bone mineralisation in children with NAFLD. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441188 Thu, 24 Nov 2011 05:00:00 +0100 5441188 http://www.medworm.com/index.php?rid=5441187&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04927.x Conclusions  Although there is no compelling evidence favouring either of the two most commonly used bowel preparation regimens, this may reflect shortcomings in study design. Where studies have ensured comparable dosage, or the clinically relevant outcome of proximal bowel clearance is considered, PEG‐based regimens offer the most effective option. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441187 Thu, 24 Nov 2011 05:00:00 +0100 5441187 http://www.medworm.com/index.php?rid=5441186&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04922.x Conclusion  In this prospective trial of pH‐guided treatment, neither positive nor negative results of initial pH monitoring accurately predicted response to therapy. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441186 Thu, 24 Nov 2011 05:00:00 +0100 5441186 http://www.medworm.com/index.php?rid=5441185&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04923.x Conclusions  Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441185 Thu, 24 Nov 2011 05:00:00 +0100 5441185 http://www.medworm.com/index.php?rid=5441184&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04925.x Conclusions  These data suggest that methotrexate is effective in terms of initial response in Crohn’s disease patients who have failed, or are intolerant of, thiopurines. However, efficacy is not sustained in the long term. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5441184 Thu, 24 Nov 2011 05:00:00 +0100 5441184 http://www.medworm.com/index.php?rid=5422288&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04910.x Conclusions  The Constipation‐Related Disability Scale is the first instrument that assesses the impact of constipation on daily activities. There is evidence of strong reliability and validity of the instrument. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5422288 Sat, 19 Nov 2011 06:34:30 +0100 5422288 http://www.medworm.com/index.php?rid=5408301&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04898.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408301 Wed, 16 Nov 2011 21:39:57 +0100 5408301 http://www.medworm.com/index.php?rid=5408292&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04883.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408292 Wed, 16 Nov 2011 21:39:44 +0100 5408292 http://www.medworm.com/index.php?rid=5408291&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04885.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408291 Wed, 16 Nov 2011 21:39:43 +0100 5408291 http://www.medworm.com/index.php?rid=5408290&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04872.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408290 Wed, 16 Nov 2011 21:39:41 +0100 5408290 http://www.medworm.com/index.php?rid=5408289&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04889.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408289 Wed, 16 Nov 2011 21:39:40 +0100 5408289 http://www.medworm.com/index.php?rid=5408288&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04852.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408288 Wed, 16 Nov 2011 21:39:38 +0100 5408288 http://www.medworm.com/index.php?rid=5408286&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04918.x Conclusions  The severity of dyspeptic symptom generation induced by direct acid infusion into the stomach was significantly greater in functional dyspepsia subjects than in healthy controls, suggesting that hypersensitivity to acid is one of the important mechanisms of the development of symptoms in functional dyspepsia patients. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408286 Wed, 16 Nov 2011 21:38:58 +0100 5408286 http://www.medworm.com/index.php?rid=5408287&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04904.x Conclusions  Patients with GERD‐related noncardiac chest pain should be treated with at least double dose PPI. The primary treatment for non‐GERD‐related noncardiac chest pain, regardless if oesophageal dysmotility is present, is pain modulators. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5408287 Sun, 13 Nov 2011 05:00:00 +0100 5408287 http://www.medworm.com/index.php?rid=5387080&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04901.x Conclusion  Most GERD patients remain stable or improve over a 5‐year observation period under current routine clinical care. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387080 Wed, 09 Nov 2011 05:00:00 +0100 5387080 http://www.medworm.com/index.php?rid=5387082&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04907.x Conclusions n = 1 studies in rare conditions allow drug efficacy assessment. Prucalopride relieves symptoms in selected patients with chronic pseudo‐obstruction. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387082 Tue, 08 Nov 2011 05:00:00 +0100 5387082 http://www.medworm.com/index.php?rid=5387081&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04902.x Conclusions  Ten‐day sequential therapy is more effective and equally tolerated for eradication of H. pylori infection compared with standard triple therapy. Sequential therapy may have a role as first‐line treatment for H. pylori infection. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387081 Tue, 08 Nov 2011 05:00:00 +0100 5387081 http://www.medworm.com/index.php?rid=5387085&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04903.x Conclusion  We found several novel independent predictors of rapid virological response, including BMI, AST/ALT ratio, ferritin, platelets, LDL, diabetes and type of PEG‐IFN prescribed, which may be useful in guiding treatment decisions in routine medical practice. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387085 Mon, 07 Nov 2011 05:00:00 +0100 5387085 http://www.medworm.com/index.php?rid=5387084&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04914.x Conclusions  Fatigue in IBD is common regardless of anaemia or iron deficiency. Fatigue in IBD is most marked for patients <60 years of age. Stratifying for gender and age is necessary when analysing fatigue, as fatigue is expressed differently between groups. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387084 Mon, 07 Nov 2011 05:00:00 +0100 5387084 http://www.medworm.com/index.php?rid=5387083&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04916.x Conclusions  Our analysis shows that caffeine intake is independently associated with a lower risk for NAFLD suggesting a potential protective effect. These data necessitate further research to elucidate the mechanism by which caffeine can protect against NAFLD. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387083 Mon, 07 Nov 2011 05:00:00 +0100 5387083 http://www.medworm.com/index.php?rid=5387087&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04890.x Conclusions  The use of PPIs as a class did not modify the protective effect of clopidogrel, but its use was associated with major adverse cardiovascular events itself, particularly among patients having used PPIs before percutaneous coronary intervention. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387087 Fri, 04 Nov 2011 04:00:00 +0100 5387087 http://www.medworm.com/index.php?rid=5387086&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04912.x Conclusions  Thiazolidinediones significantly improve ballooning degeneration, lobular inflammation, steatosis and combined necroinflammation in patients with NASH. Pioglitazone may improve fibrosis. Larger randomised, placebo‐controlled clinical trials are needed to examine the efficacy of thiazolidinediones in improving NASH fibrosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387086 Fri, 04 Nov 2011 04:00:00 +0100 5387086 http://www.medworm.com/index.php?rid=5387090&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04905.x Conclusions  Based on the literature data, we provide a therapeutic algorithm for thiopurines therapy with starting dose recommendations depending on TPMT status and thereafter dose adjustments according to five metabolite profiles identified with therapeutic drug monitoring (TDM). This algorithm allows a dosage individualisation to optimise the management of patients under thiopurine. Furthermore, identification of new pharmacogenetic biomarkers is promising for ensuring maximal therapeutic response to thiopurines with a minimisation of the risk for adverse events. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387090 Wed, 02 Nov 2011 04:00:00 +0100 5387090 http://www.medworm.com/index.php?rid=5387089&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04908.x Conclusions  Anti‐α‐actinin Abs at baseline appear to predict treatment response and therefore they might be used for monitoring treatment outcome in AIH‐1. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387089 Wed, 02 Nov 2011 04:00:00 +0100 5387089 http://www.medworm.com/index.php?rid=5387088&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04911.x Conclusions  In this predominantly genotype 1 cohort, shortening therapy to 24 weeks in patients with a week‐4 response and 36 weeks in those with a week‐8 response produced SVR rates that were similar to a 48‐week regimen. Lengthening treatment to 72 weeks did not improve SVR rates. Genotype 1 patients with RVR can be treated for 24 weeks (clinicaltrials.gov NCT00483938). (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387088 Wed, 02 Nov 2011 04:00:00 +0100 5387088 http://www.medworm.com/index.php?rid=5400852&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04915.x Conclusion  Co‐morbid diabetes in patients with Crohn’s disease predicts a greater need for surgical intervention. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5400852 Tue, 01 Nov 2011 04:00:00 +0100 5400852 http://www.medworm.com/index.php?rid=5387079&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04906.x Conclusions  The study demonstrates high mortality rates in patients hospitalised during 1998–2000 for CD, especially in patients over 50. Elective surgery is associated with lower mortality than emergency surgery or medical therapy. Further study is needed to determine whether these patterns have changed following the introduction of biological treatment. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5387079 Tue, 01 Nov 2011 04:00:00 +0100 5387079 http://www.medworm.com/index.php?rid=5360495&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04897.x Conclusions  SAFE biopsy and the Fibropaca algorithm have excellent performance for liver fibrosis in hepatitis C, allowing a significant reduction in the need for liver biopsies. They can be useful in clinical practice and for large‐scale screening. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5360495 Mon, 31 Oct 2011 04:19:17 +0100 5360495 http://www.medworm.com/index.php?rid=5360496&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04896.x Conclusion  Larger controlled clinical trials are needed to demonstrate any potential beneficial effect of sorafenib on portal hypertension in patients with cirrhosis. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5360496 Thu, 27 Oct 2011 04:00:00 +0100 5360496 http://www.medworm.com/index.php?rid=5336016&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04887.x Conclusion  Although a decrease in the H. pylori eradication rate after triple therapy has been suggested in recent years, cure rates with this regimen did not change in Spain between 1997 and 2008. However, this by no means indicates that the efficacy of standard triple therapy in Spain is acceptable, as it has been calculated to be around only 80%. Therefore, it is evident that new strategies to improve first‐line treatment are urgently needed. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5336016 Sat, 22 Oct 2011 05:34:27 +0100 5336016 http://www.medworm.com/index.php?rid=5324107&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04856.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324107 Tue, 18 Oct 2011 05:50:07 +0100 5324107 http://www.medworm.com/index.php?rid=5324106&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04868.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324106 Tue, 18 Oct 2011 05:50:04 +0100 5324106 http://www.medworm.com/index.php?rid=5324105&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04853.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324105 Tue, 18 Oct 2011 05:50:00 +0100 5324105 http://www.medworm.com/index.php?rid=5324104&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04858.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324104 Tue, 18 Oct 2011 05:49:57 +0100 5324104 http://www.medworm.com/index.php?rid=5324103&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04859.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324103 Tue, 18 Oct 2011 05:49:49 +0100 5324103 http://www.medworm.com/index.php?rid=5324102&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04854.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324102 Tue, 18 Oct 2011 05:49:46 +0100 5324102 http://www.medworm.com/index.php?rid=5324097&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04871.x Conclusion  The FACIT‐F scale is a reliable and valid instrument for measuring fatigue in IBD. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324097 Tue, 18 Oct 2011 05:48:57 +0100 5324097 http://www.medworm.com/index.php?rid=5336017&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04888.x Conclusions  Age and HBV DNA levels are independent parameters of HBsAg levels. During the natural course of CHB infection, HBsAg levels decrease with age and disease progression, but the patterns are significantly different between the immune phases of CHB. This information may contribute to our understanding of the immunopathogenesis of chronic hepatitis B and management involving HBsAg quantification. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5336017 Tue, 18 Oct 2011 04:00:00 +0100 5336017 http://www.medworm.com/index.php?rid=5324101&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04867.x Conclusions  Prophylactic treatment with escitalopram is effective in the prevention of psychiatric side‐effects during interferon‐based treatment of hepatitis C. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324101 Mon, 17 Oct 2011 04:00:00 +0100 5324101 http://www.medworm.com/index.php?rid=5324100&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04870.x Conclusions  Based on the currently available data, a causal relationship between GERD and idiopathic pulmonary fibrosis cannot be established. There is scant evidence about antireflux therapy in idiopathic pulmonary fibrosis patients. There may be an association between lung and oesophageal involvement in systemic sclerosis and mixed connective tissue disease, but a causal relationship cannot be established. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324100 Mon, 17 Oct 2011 04:00:00 +0100 5324100 http://www.medworm.com/index.php?rid=5324099&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04874.x Conclusions  Severe hypochlorhydria generated by PPI use leads to bacterial colonisation and increased susceptibility to enteric bacterial infection. The clinical implication of chronic PPI use among hospitalized patients placed on antibiotics and travellers departing for areas with high incidence of diarrhoea should be considered by their physicians. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324099 Mon, 17 Oct 2011 04:00:00 +0100 5324099 http://www.medworm.com/index.php?rid=5324098&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04873.x Conclusions  The current evidence; although of a poor quality, appears to support the use of tacrolimus in Crohn’s disease. High quality randomised controlled trials are needed. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5324098 Mon, 17 Oct 2011 04:00:00 +0100 5324098 http://www.medworm.com/index.php?rid=5304544&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04849.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304544 Wed, 12 Oct 2011 05:41:11 +0100 5304544 http://www.medworm.com/index.php?rid=5304543&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04838.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304543 Wed, 12 Oct 2011 05:41:09 +0100 5304543 http://www.medworm.com/index.php?rid=5304542&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04836.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304542 Wed, 12 Oct 2011 05:41:07 +0100 5304542 http://www.medworm.com/index.php?rid=5304541&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04815.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304541 Wed, 12 Oct 2011 05:41:05 +0100 5304541 http://www.medworm.com/index.php?rid=5304540&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04804.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304540 Wed, 12 Oct 2011 05:41:04 +0100 5304540 http://www.medworm.com/index.php?rid=5304539&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04850.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304539 Wed, 12 Oct 2011 05:41:02 +0100 5304539 http://www.medworm.com/index.php?rid=5304538&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04845.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304538 Wed, 12 Oct 2011 05:41:00 +0100 5304538 http://www.medworm.com/index.php?rid=5304537&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04846.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304537 Wed, 12 Oct 2011 05:40:58 +0100 5304537 http://www.medworm.com/index.php?rid=5304536&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04841.x (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304536 Wed, 12 Oct 2011 05:40:57 +0100 5304536 http://www.medworm.com/index.php?rid=5304535&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04839.x Conclusions  The present article states several misconceptions in the management of H. pylori‐associated gastric MALT‐lymphoma in clinical practice, reviews the related scientific evidence and proposes the adequate attitude in each case. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304535 Wed, 12 Oct 2011 05:40:42 +0100 5304535 http://www.medworm.com/index.php?rid=5304533&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04861.x Conclusions  Aetiology is a major factor influencing the performance of liver fibrosis biomarkers. Even after correction for DANA, APRI and Fibrotest‐Fibrosure exhibit the best performance. However, liver biopsy is not replaceable, especially to diagnose ≥F2 and in HCV carriers with normal ALT. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304533 Wed, 12 Oct 2011 05:40:24 +0100 5304533 http://www.medworm.com/index.php?rid=5304534&cid=s_32539_13_f&fid=32539&url=http%3A%2F%2Fdx.doi.org%2F10.1111%252Fj.1365-2036.2011.04857.x Conclusions  Paediatric UC patients had more extensive disease, were more often treated with systemic steroids and AZA, had a higher frequency of steroid dependency and a more severe disease course compared to adult UC patients. No differences were found when comparing paediatric and adult CD patients. (Source: Alimentary Pharmacology and Therapeutics) Alimentary Pharmacology and Therapeutics journals http://www.medworm.com/rss/comments.php?id=5304534 Sun, 09 Oct 2011 04:00:00 +0100 5304534